Broadwood Partners buys 570,184 Insight Molecular Diagnostics shares for $2.04 million

• Broadwood Partners reported open-market purchases totaling 570,184 Insight Molecular Diagnostics common shares at prices between $3.50 and $3.64.
• Position rose to 12,684,884 shares held directly.
• Neal C. Bradsher, president of Broadwood Capital, reported direct ownership of 157 shares.
• Broadwood Partners reported warrants to purchase 150,093 common shares at an exercise price of $30.60.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000919574-26-002414), on April 27, 2026, and is solely responsible for the information contained therein.